The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISH 2022 | Mechanism of action & use of daratumumab in multiple myeloma
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, gives an overview of the mechanism of action of daratumumab in multiple myeloma, commenting on its use in the frontline and relapsed/refractory (R/R) settings in transplant-eligible and transplant-ineligible patients. This interview took place at the 38th World Congress of the International Society of Hematology (ISH) 2022.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
